<DOC>
	<DOCNO>NCT00665002</DOCNO>
	<brief_summary>The purpose study determine whether WT-1 vaccine cause immune response safe . The WT-1 vaccine make protein piece patient 's immune system recognize abnormal .</brief_summary>
	<brief_title>Pilot Trial WT-1 Analog Peptide Vaccine Patients With Myeloid Neoplasms</brief_title>
	<detailed_description>Design : This pilot trial evaluate safety immunogenicity WT-1 peptide vaccine patient hematologic malignancy . Ten patient acute myelogenous leukemia ( AML ) advance myelodysplastic syndrome ( MDS ) , enrol . Patients vaccinated preparation WT-1-derived native synthetic peptide plus immunologic adjuvant Montanide ISA 51 VG ( Seppic Pharmaceuticals , Fairfield , NJ ) Sargramostim ( GM-CSF ) . One dose level test . Patients receive 6 injection WT-1 vaccine . Doses give every 2 week . Each vaccine give different location skin arm leg . Patients monitor 30 minute vaccination . WT-1 vaccine give another substance , Montanide , clump WT-1 vaccine improve immune response . Patients also receive injection Sargramostim ( GM-CSF ) 2 day vaccination day WT-1 injection spot . Sargramostim ( GM-CSF ) stimulate body 's white blood cell boost immune response . Patients may teach Sargramostim ( GM-CSF ) injection case patient give log sheet record injection time location . If , need come additional 24 study visit . To monitor health receive vaccine , patient need follow test procedure part regular cancer care . - History physical examination every 2 week - Complete blood count ( CBC ) comprehensive panel every 2 week - Bone marrow aspirate week 14 patient acute myelogenous leukemia myelodysplastic syndrome . Patients need test procedure see whether vaccine cause immune response : - A skin test perform patient start study 8th 14th week small amount vaccine place skin . Two day later , site check see whether bump swell form . Another substance typically cause mild reaction ( mumps ) also place skin measure whether normal immune reaction . - We take 7 tablespoon blood measure immune response . About 1 tablespoon blood take measure level WT-1 blood . Blood sample take prior receive first vaccination prior receive vaccination week 6 12 . If vaccine cause patient immune response , cancer grow , may continue receive WT-1 vaccination monthly 6 month . If occurs , patient compute tomography ( CT ) scan bone marrow test immunology blood test 2 week 9th 12th vaccination .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Cytologic histologic diagnosis acute myelogenous leukemia myelodysplastic syndrome confirm Moffitt Cancer Center . Patients acute myelogenous leukemia complete induction chemotherapy , achieve first complete remission ( CR ) 1 2 , complete planned postremission therapy ( discretion treat physician ) , plan allogenic autologous transplant . Patients myelodysplastic syndrome accord International Prognostic Scoring System ( IPSS ) category Int2 great , disease relapse , progress , respond least 1 prior course approve therapy MDS ( i.e . hypomethylating agent lenalidomide ) . Patients AML/MDS must document WT1 + disease . For purpose study , may either demonstration WT1 protein pretreatment bone marrow biopsy detectable disease RQPCR . For patient bone marrow aspirate available possible ( e.g . `` dry tap '' ) , peripheral blood sample may use WT1 screen . In case , 10 cc peripheral blood collect heparinized tube . At least 4 week must elapse patient 's last chemotherapy radiation treatment first vaccination . Karnofsky performance status ≥ 70 % Hematologic parameter : Absolute neutrophil count ≥ 1000/mcL ( except MDS , parameter ≥ 500/mcL ) Platelets &gt; 50 K/mcL ( except MDS parameter &gt; 25 K/mcL transfusion dependent ) Biochemical parameter : Total bilirubin ≤ 2.0 mg/dl Aspartic transaminase ( AST ) Alanine transaminase ( ALT ) ≤ 2.5 x upper limit normal Creatinine ≤ 2.0 mg/dl Pregnant lactate woman Patients leptomeningeal disease Patients active infection require systemic antibiotic , antiviral , antifungal treatment Patients serious unstable medical illness Patients take systemic corticosteroid Patients central nervous system ( CNS ) involvement cancer/leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Myeloid</keyword>
	<keyword>Monocytic</keyword>
	<keyword>Hematopoietic</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>